医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

InVivo Therapeutics to Present at 4th International Neural Regeneration Symposium in China

2014年06月30日 PM09:30
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass.

InVivo Therapeutics Holdings Corp. (NVIV) announced today that InVivo’s Director of Research Richard Layer, Ph.D., has been invited to speak at the Joint Symposium of the 4th International Neural Regeneration Symposium (INRS2014), 9th Asia Pacific Symposium on Neural Regeneration (APSNR2014), and 6th International Spinal Cord Injury Treatment and Trials Symposium (ISCITT2014), to be held September 6-8, 2014 in Nanjing, China (website: http://www.inrs-nrr.org/CN/model/index_en.shtml).

“It is a great honor to be invited to speak at this international symposium,” Dr. Layer said. “InVivo is a leader in the field, and I look forward to presenting the company’s approach to development and translation of new treatments for spinal cord injury to my international colleagues.” The goal of the Joint Symposium is to provide an international platform for presenting new discoveries, to exchange new ideas, to stimulate new collaborations, to promote translation from basic science to the clinic, and to educate professionals in the field of neural regeneration.

Dr. Layer will present an overview of the company’s biomaterials technology platform, including its degradable polymer Neuro-Spinal Scaffold. Recently, following approval from the U.S. Food and Drug Administration (FDA), InVivo Therapeutics initiated a clinical study of its Neuro-Spinal Scaffold. This study is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in up to five human subjects with acute thoracic spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011 the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.

CONTACT

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor
Relations
bluque@invivotherapeutics.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent